ReviewChinese medicine2023
Potential traditional Chinese medicines with anti-inflammation in the prevention of heart failure following myocardial infarction.
Review in Chinese medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Efficacy and safety of Salvia miltiorrhiza and ligustrazine injection for heart failure: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Systematic Review of Preclinical Studies on the Efficacy and Mechanisms of Herbal Medicines in Post-Myocardial Infarction Heart Failure with Reduced Ejection Fraction.Medicina (Kaunas, Lithuania) · 2024Pooled it
- The neutrophil-to-lymphocyte ratio: a psychoneuroimmunological nexus linking depression and cardiovascular comorbidity.European archives of psychiatry and clinical neuroscience · 2026Article
- The sensitivity of adult zebrafish to clinically relevant neuroactive (sedative) effects of extracts of selected traditional Chinese medicine herbs.Psychopharmacology · 2026Article
- Trem1 exacerbates myocardial infarction-induced heart failure by inactivating the Rap1 pathway.Journal of cardiothoracic surgery · 2026Article
- Metabolomics-Driven Precision Prevention and Treatment of Heart Failure with Traditional Chinese Medicine: From Mechanistic Insights to Metabolic Network Regulation.Drug design, development and therapy · 2026Review
- Bibliometric Analysis of Research on Traditional Chinese Medicine Treatment of Myocardial Infarction from 2007 to 2024 Based on the Web of Science Database.Current medicinal chemistry · 2026Article
- Tianhuang formula attenuates cardiomyocyte pyroptosis in myocardial infarction by suppressing oxidative stress and the cGAS-STING-NLRP3 axis.Frontiers in immunology · 2026Article
- Icariin-mediated structural stabilization of TNF-α triggers a pro-regenerative signaling switch for endothelial recovery after myocardial infarction.Frontiers in pharmacology · 2026Article
- "The Ameliorative Effect of Interleukin-17A Neutralization on Doxorubicin-Induced Cardiotoxicity by Modulating the NF-κB/NLRP3/Caspase-1/IL-1β Signaling Pathway in Rats".Inflammation · 2025Article
- Association between inflammatory burden index and risk of heart failure: evidence from NHANES 2003-2017.BMC cardiovascular disorders · 2025Article
- Article
- Exploring molecular characteristics and interactions of blood stasis syndrome in ischemic heart failure by integrated multi-omics.Frontiers in molecular biosciences · 2025Article
- Modified Taohong Siwu Decoction Improved Cardiac Function after Myocardial Infarction by Activating PI3K/Akt Signaling Pathway.Current pharmaceutical design · 2025Article
- Sini decoction alleviates inflammation injury after myocardial infarction through regulating arachidonic acid metabolism.Chinese herbal medicines · 2025Article
- Kuanxiong aerosol attenuates post-myocardial infarction heart failure by immune modulation via the NOTCH1 pathway.American journal of translational research · 2025Article
- Causal effects of inflammatory cytokines on cardiovascular diseases: Insights from genetic evidence.Heliyon · 2024Article
- Effectiveness and mechanism of Huoxin pill on heart failure after percutaneous coronary intervention: Study protocol for a double-blind, randomised, placebo-controlled parallel trial.Contemporary clinical trials communications · 2024Article
- Therapeutic potentials of allicin in cardiovascular disease: advances and future directions.Chinese medicine · 2024Review
- Nanocurcumin in myocardial infarction therapy: emerging trends and future directions.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation plays an important role in the development of heart failure (HF) after myocardial infarction (MI). Suppression of post-infarction inflammatory cascade has become a new strategy to delay or block the progression of HF. At present, there are no approved anti-inflammatory drugs used to prevent HF following MI. Traditional Chinese medicine (TCM) has been used clinically for cardiovascular disease for a long time. Here, we summarized the recent progress about some TCM which could both improve cardiac function and inhibit inflammation in patients or experimental models with MI or HF, in order to provide evidence for their potential application in reducing the onset of HF following MI. Among them, single Chinese medicinal herbs (eg. Astragalus and Salvia miltiorrhiza) and Chinese herbal formulas (eg. Gualou Xiebai Decoction and Sini Tang) are discussed separately. The main targets for their anti-inflammation effect are mainly involved the TLR4/NF-κB signaling, as well as pro-inflammatory cytokines IL-1β, IL-6 or TNF-α. It is worthy of further evaluating their potential, experimentally or clinically, in the prevention or delay of HF following MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.